% | $
Quotes you view appear here for quick access.


  • jwbenningston jwbenningston Oct 31, 2013 1:31 PM Flag

    Read the Failed Efficacy results on JACC Article

    This will never be approved in the United States.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • This conversation is moot. It's already approved in 40+ other countries AND the FDA is so confident that they put it into the stage 3 fastrack program. This is as good as a done deal. FInd another stock to short. This one is going UP.

      Sentiment: Strong Buy

    • JACC is a organization that filters different points of view. Why don't you include the letter to the editor at JACC from Singapore, where the major municipal hospital there uses Levosimendan to forestall re-hospitalizations of very sick heart failure patients who are awaiting mechanical assist devises for their hearts! Levosimendan is a life saver when used responsibly on patients in severe need who are properly monitored for hypotension and arrhythmias.

      Sentiment: Buy

    • Please talk about something you understand, you have no clue what you are saying

      Sentiment: Strong Buy

    • matt.staudt.jr Oct 31, 2013 1:38 PM Flag

      BS! Here is the article. All good findings. Don't know what you are referring to and I love how you all just throw things out there and don't back it up with a link....LONG OXBT!!!!

      Sentiment: Strong Buy

      • 1 Reply to matt.staudt.jr
      • matt.staudt.jr Oct 31, 2013 1:51 PM Flag


        Background This study evaluated the efficacy and safety of levosimendan, a positive inotropic drug with vasodilator effects, given intravenously to patients with acutely decompensated heart failure (ADHF).

        Methods We performed 2 sequential trials, the first to develop a new measure of efficacy in 100 patients, and the second to use this measure to evaluate levosimendan in an additional 600 patients. Patients admitted with ADHF received placebo or intravenous levosimendan for 24 h in addition to standard treatment. The primary endpoint was a composite that evaluated changes in clinical status during the first 5 days after randomization.

        Results In the 600-patient trial, more levosimendan than placebo patients (58 vs. 44) were improved at all 3 pre-specified time points (6 h, 24 h, and 5 days), whereas fewer levosimendan patients (58 vs. 82) experienced clinical worsening (p = 0.015 for the difference between the groups). These differences were apparent, despite more frequent intensification of adjunctive therapy in the placebo group (79 vs. 45 patients). Improvements in patient self-assessment and declines in B-type natriuretic peptide levels with levosimendan persisted for 5 days and were associated with reduced length of stay (p = 0.009). Similar findings were present in the 100-patient pilot trial. Levosimendan was associated with more frequent hypotension and cardiac arrhythmias during the infusion period and a numerically higher risk of death across the 2 trials (49 of 350 on a regimen of levosimendan vs. 40 of 350 on a regimen of placebo at 90 days, p = 0.29).

        Conclusions In patients with ADHF, intravenous levosimendan provided rapid and durable symptomatic relief. As dosed in this trial, levosimendan was associated with an increased risk of adverse cardiovascular events. (Evaluation of Intravenous Levosimendan Efficacy in the Short Term Treatment of Decompensated Chronic Heart Failure; NCT00048425)

        Sentiment: Strong Buy

    • You are a funny dude! Must be really hurting to watch it from the sidelines!

      Sentiment: Strong Buy

    • no thanks. i think i''ll just enjoy the squeeze past the pre-reverse split level, then move on.

    • You dont even know what u saying???

      should take a different approach ...COVER...